JP2020503891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503891A5 JP2020503891A5 JP2019551736A JP2019551736A JP2020503891A5 JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5 JP 2019551736 A JP2019551736 A JP 2019551736A JP 2019551736 A JP2019551736 A JP 2019551736A JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cell
- car
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017202A JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432302P | 2016-12-09 | 2016-12-09 | |
| US62/432,302 | 2016-12-09 | ||
| PCT/EP2017/082292 WO2018104562A1 (en) | 2016-12-09 | 2017-12-11 | Engineered natural killer cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Division JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503891A JP2020503891A (ja) | 2020-02-06 |
| JP2020503891A5 true JP2020503891A5 (enExample) | 2021-01-21 |
| JP7228900B2 JP7228900B2 (ja) | 2023-02-27 |
Family
ID=60937693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551736A Active JP7228900B2 (ja) | 2016-12-09 | 2017-12-11 | 操作されたナチュラルキラー細胞およびその使用 |
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799536B2 (enExample) |
| EP (4) | EP3581190B1 (enExample) |
| JP (2) | JP7228900B2 (enExample) |
| KR (1) | KR20190114966A (enExample) |
| CN (2) | CN110248669B (enExample) |
| AU (1) | AU2017371517B2 (enExample) |
| BR (1) | BR112019011450A2 (enExample) |
| CA (1) | CA3045386A1 (enExample) |
| DK (2) | DK3454871T3 (enExample) |
| ES (3) | ES2875005T3 (enExample) |
| MX (1) | MX2019006598A (enExample) |
| WO (1) | WO2018104562A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101520534B1 (ko) | 2012-05-07 | 2015-05-21 | 고려대학교 산학협력단 | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 |
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP4650005A3 (en) * | 2016-07-15 | 2026-01-28 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| EP3581190B1 (en) | 2016-12-09 | 2021-03-10 | ONK Therapeutics Limited | Engineered natural killer cells and uses thereof |
| AU2019271366B2 (en) * | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
| KR102907902B1 (ko) | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| TWI785268B (zh) * | 2018-08-29 | 2022-12-01 | 中央研究院 | 用於治療癌症的自然殺手細胞與環磷醯胺的組合 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| KR102292657B1 (ko) * | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| CN114867485A (zh) * | 2019-10-31 | 2022-08-05 | 全国儿童医院研究所 | Cd38敲除的原代和扩增的人nk细胞的生成 |
| WO2021146521A1 (en) * | 2020-01-16 | 2021-07-22 | Acepodia Biotechnologies Ltd. | A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
| EP4205761A4 (en) * | 2020-08-27 | 2024-05-29 | Cellid Co., Ltd | NOVEL RECOMBINANT CORONAVIRUS SPIKE PROTEIN, POLYNUCLEOTIDE, VECTOR WITH POLYNUCLEOTIDE AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION WITH VECTOR |
| EP4204546A1 (en) | 2020-08-31 | 2023-07-05 | City of Hope | Novel cell lines, methods of producing natural killer cells and uses thereof |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| KR20220091426A (ko) | 2020-12-23 | 2022-06-30 | 주식회사 휴먼셀바이오 | 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물 |
| JP2024522756A (ja) | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
| US20240327521A1 (en) * | 2021-07-29 | 2024-10-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Synthetic nucleic acid elements for enhancing car t cell efficacy |
| US20250145693A1 (en) * | 2021-09-18 | 2025-05-08 | Sunnybay Biotech, Inc. | Herv-k antibody, cell, vaccine, and drug therapeutics |
| US20240352123A1 (en) * | 2021-12-03 | 2024-10-24 | University Of Utah Research Foundation | High selective cd229 antigen binding domains and methods of use |
| US20250375524A1 (en) | 2022-06-30 | 2025-12-11 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| CN120091827A (zh) | 2022-11-10 | 2025-06-03 | 昂克医疗有限公司 | 使用免疫调节药物的联合疗法 |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| CN121969385A (zh) | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| EP4788796A1 (en) | 2023-10-05 | 2026-08-12 | ONK Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| KR20250118299A (ko) | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
| WO2025184169A1 (en) * | 2024-02-26 | 2025-09-04 | The Regents Of The University Of California | Oleate-mediated enhancement of human natural killer cell function |
| WO2025239292A1 (ja) * | 2024-05-15 | 2025-11-20 | 株式会社Cured | 改変ナチュラルキラー細胞株 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2196474A3 (en) * | 2003-02-14 | 2010-12-15 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| PL2081595T3 (pl) | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP2076285A4 (en) | 2006-10-19 | 2010-06-30 | Merck Sharp & Dohme | ANTIBODY ANTAGONISTS OF INTERLEUKIN 13 RECEPTOR 1 |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| CN105339498A (zh) | 2013-03-07 | 2016-02-17 | 贝勒医学院 | 癌症中靶向cd138 |
| DK3105317T3 (en) * | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| EP3104866A4 (en) * | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3237436B1 (en) | 2014-12-24 | 2019-05-01 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of molecules |
| HK1246180A1 (zh) | 2014-12-31 | 2018-09-07 | Celgene Corporation | 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法 |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CA3172801A1 (en) | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| EP3828266B1 (en) | 2015-07-29 | 2022-11-23 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| WO2018104554A1 (en) | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Improved nk-based cell therapy |
| EP3581190B1 (en) * | 2016-12-09 | 2021-03-10 | ONK Therapeutics Limited | Engineered natural killer cells and uses thereof |
| WO2019201629A1 (en) | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with antibodies in cancer therapy |
-
2017
- 2017-12-11 EP EP19176141.0A patent/EP3581190B1/en active Active
- 2017-12-11 MX MX2019006598A patent/MX2019006598A/es unknown
- 2017-12-11 ES ES19176141T patent/ES2875005T3/es active Active
- 2017-12-11 CN CN201780085686.0A patent/CN110248669B/zh active Active
- 2017-12-11 CN CN202311063691.5A patent/CN117305250A/zh active Pending
- 2017-12-11 JP JP2019551736A patent/JP7228900B2/ja active Active
- 2017-12-11 EP EP21160170.3A patent/EP3895712B1/en not_active Revoked
- 2017-12-11 AU AU2017371517A patent/AU2017371517B2/en not_active Ceased
- 2017-12-11 BR BR112019011450-5A patent/BR112019011450A2/pt not_active IP Right Cessation
- 2017-12-11 CA CA3045386A patent/CA3045386A1/en active Pending
- 2017-12-11 EP EP17825774.7A patent/EP3454871B1/en active Active
- 2017-12-11 EP EP22179362.3A patent/EP4104841A1/en active Pending
- 2017-12-11 DK DK17825774.7T patent/DK3454871T3/da active
- 2017-12-11 KR KR1020197019363A patent/KR20190114966A/ko not_active Ceased
- 2017-12-11 DK DK19176141.0T patent/DK3581190T3/da active
- 2017-12-11 ES ES21160170T patent/ES2926397T3/es active Active
- 2017-12-11 US US15/837,576 patent/US10799536B2/en active Active
- 2017-12-11 ES ES17825774T patent/ES2746856T3/es active Active
- 2017-12-11 WO PCT/EP2017/082292 patent/WO2018104562A1/en not_active Ceased
-
2020
- 2020-08-31 US US17/008,506 patent/US12534536B2/en active Active
-
2023
- 2023-02-07 JP JP2023017202A patent/JP2023052980A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| PH12018501778A1 (en) | Antibodies to tigit | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2020526214A5 (enExample) | ||
| JP2012254092A5 (enExample) | ||
| JP2014505463A5 (enExample) | ||
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2017518258A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| JP2017513478A5 (enExample) | ||
| WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
| JP2017537972A5 (enExample) | ||
| JP2018524326A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| JP2017508466A5 (enExample) | ||
| JP2015527070A5 (enExample) |